univers coverag
calendar event
review data releas payer psychiatrist edt
regulatori event fda adcom gastrointestin drug pediatr stannsoporfin
infect link note
medic meet associ research vision ophthalmolog nite
essenti protein engin summit american societi pediatr hematology/oncolog
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
aospin global spine congress intern societi cellular therapi american
societi breast surgeon american geriatr societi
d/g mp cyno still overhang nt ep upsid potenti limit pt
 methodolog ep
bottom line downgrad mp op lower pt vs
convict near-term ep estim upsid diminish -- -especi tax-benefit-
relat ep cushion basic get use mitig reduc sale outlook
lower cyno expect cyno compani achil heel sinc acq close
begin question whether busi struggl might structur
natur vs pure sale forc execution/backfil management assum meanwhil still declin
gyn franchis also turnaround time uncertain slow us molecular growth ex-
blood screen revenue add grow set headwinds/uncertainti ultim view tough
end-market thu move mp rate pend greater confid ep upsid potenti
cyno number begin move need come and/or organ cc
revenue growth sustain move back msd territori faster-than expect
lower estim pt vs
sale slightli ahead expect best qualiti
revenue growth outlook decreas primarili cyno turnaround go take longer origin
think turnaround cyno could take longer-than project there guarante management
lower/upd cyno outlook right project proven move target almost
qtr row
ep guidanc reiter despit reduc sale outlook think upward ep revis limit
kol address controversi ahead multipl data readout
bottom line adap clinical-stag biotechnolog compani pioneer develop
t-cell-bas immunotherapi cancer adap t-cell receptor tcr platform could potenti
address solid tumor view transform cell therapi space success adap
proprietari platform enabl gener engin tcr-base cell therapi permit target
wide rang antigen exploit monoclon antibodi chimer antigen
receptor -t view adap leader potenti disrupt tcr field howev
also view execut key adap stori natur consequ adap leadership posit
rel new tcr field develop risk includ time clinic progress due hurdl
associ enrol screen patient involv physician educ discoveri true
rate antigen express clinic vs publish literatur well human leukocyt antigen hla
restrict view potenti import valid year adap tcr platform multipl
data readout expect includ adap proprietari clinic stage tcr program
afp repres key valu driver compani ahead upcom data
readout spoke three medacorp kol highlight view opportun t-cell
therapi solid tumor adap tcr approach specif describ within
updat american societi clinic oncolog includ
catalyst repres key opportun platform valid
takeaway kol convers includ
bottom line fda adcom vote favor approv plazomicin complic urinari
tract infect plazomicin bloodstream infect bsi popul limit
treatment option disappoint stock major valuat
resid treatment carbapenem-resist enterobacteriacea outcom
vote still suggest plazomicin approv label cuti furthermor
commentari physician panel member suggest potenti off-label use upon approv
similar avycaz gener sale
stock trade follow adcom document encourag today
decis would expect pullback investor review potenti impact peak sale
model assum off-label use plazomicin similar avycaz continu believ
import driver plazomicin sale initi reserv
data may may includ label also note key compar accord
medacorp kol avycaz gener major sale due off-label use driven
microbiolog data howev avycaz work subset patient notabl patient
kpc mutat rang vancouv studi lo angel studi
isol result adcom may call question whether data includ
label believ minimum microbiolog data similar avycaz support use plazomicin
strain label drive off-label use potenti off-label use
corrobor commentari physician panel member would use plazomicin off-label
approv cuti
interestingli key barrier panel member vote approv bsi indic hing upon
substanti evid requir lpad approv pathway
busi solid pharmedium still weigh
ep
bottom line follow earn post decent result guidanc
exclud pharmedium lash impact reduc ep estim account
pharmedium increas long-term estim due mainli slightli favor
gross margin assumpt core distribut busi perform well quarter
manag highlight major gross profit growth driven pharmaceut
segment larg off-set headwind pharmedium addit encourag
gener deflat brand inflat appear stabl gener complianc rate
improv continu like smith acquisit view posit
specialti signific posit relationship mp also signific posit
store on-board end quarter maintain pt
core busi continu perform well mostli offset pharmedium headwind
stabil brand gener trend bode well pharma suppli chain continu strength
core pharma busi
pharmedium impact last longer initi expect
lash continu present headwind manag believ right path
outlook guid lower end previou rang due pharmedium lash headwind
 methodolog ev/ebitda adjust ebitda
bottom line rais pt report revenu ebitda ep
beat strong perform us uk uk segment rebound nice
ss revenu growth yoy improv patient day length stay lo price though
challeng nh shift referr local govern like remain appear
convert bed nurs camh children adolesc mental health servic meet
nh capac demand off-set headwind us also good quarter revenu price
lo trend improv hand facil impact volum trend compani
note expect remain swb yoy activ address staf
pressur us/uk continu enter jv open de novo add bed us
drive growth still compani remain lever may limit access capit de novo
larg scale without share rais increas ebitda mm
ebitda mm
beat revenu ebitda ep
uk rebound nice ss revenu growth yoy improv patient day lo
price
us also report good quarter revenu price lo trend improv
swb yoy activ address staf pressur us/uk
ac jv remain opportun expect add two jv chattanooga tn ohio
reiter ebitda guidanc mm midpoint line consensu
rais revenu ebitda ep estim
capit deploy opportun drive growth remain lever may
share rais larg larg acquisit
centuri cure impend legisl opioid bill expect year could provid
rais pt
revenu million
on-going delay va weigh result guid reduc
ep
bottom line wednesday even report mix result guid
reduc guid disappoint manag explain outlook
reduc due on-going delay va contract cautiou view market
environ book continu import metric view concern
commentari overshadow good book grew y/i overal
view quarter weak maintain mp pt
result weak va delay contribut revenu miss
guid reduc continu va delay put reduc fy guid risk
book growth continu despit reduct outlook lack larg opportun
market demand appear weaken core challeng ancillari product
solid quarter though invest still weigh outlook
bottom line follow call remain posit increas adjust ep
estim slightli account quarter ep stand quarter
decent oper incom guidanc enterpris retail pbm unchang
guidanc pbm divis well previou expect pbm face higher cost
op contract retail challeng continu long-term care group reimburs
pressur re-invest back busi encourag impress growth
retail revenu volum beat retail oper incom new program
work aet mp deal sound encourag maintain op rate pt
retail final turn around long-term guid disappoint
guidanc disappoint rel model
adjust ep exclud acquisit amort one-tim item exclud interest expens relat
aet transact exclud revenu earn aet deal
bottom line even esrx report mix result mostli re-affirmed prior
guidanc ep guid lower reflect suspens buy-back per merger agreement
metric maintain quarter result mix lower cost tax
made revenu slightli model compani core busi seem
track decent manag said expect achiev posit claim growth core
given good client retent sell season ytd lower estim reflect
guidanc slightli slower revenu growth off-set partial better op-ex interest expens trend
pt move given lower estim still risk around deal close
mix result ep beat achiev opex interest tax
updat releas
revenu billion ep adjust non-cash non-recur item
bottom line above-consensu result increas rev/ep outlook increas
confid compani sustain revenu growth acceler trajectori
 beyond compani increasingli begin benefit emerg product cycl robot
 trauma reiter op pt
rev/ep guidanc increas like continu leav room upsid
robot momentum build new indic way
us ex-robot spine growth trend market rate sell day adj basi
revenu million
recap pipelin track reiter op
bottom line imdz report financi result provid increment posit pipelin
updat clinic timelin consist previou guidanc link investor sentiment imdz
share neg sinc disclosur plan therapeut cancer vaccin target
trial design synovi sarcoma link link current trade enterpris valu
see upsid imdz stock current level platform continu potenti
valid clinic data readout continu view imdz therapeut cancer vaccin
platform approach credibl effort potenti overcom issu plagu field
past although continu investor caution cancer vaccin space broadli view
next month import execut period imdz multipl updat expect
catalyst event
updat phase ii plu atezolizumab soft tissu sarcoma st data continu expect
earli
imdz guid suffici cash fund oper
revenu million ep
recap track progress ali like launch assum
discount rate termin growth rate
bottom line nda ali amikacin liposom inhal suspens file
march plan link ali remain forefront focu near-term
drug candid undergo month prioriti review geograph expans plan
compani acceler pipelin drug candid may/jun
announc end pdufa date expect accord management meantim insm
continu work toward launch ali earli engag regulatori agenc
physician prepar expect advisori committe adcom panel increas manufactur
effort report cash cash equival ep loss per
share maintain pt reiter outperform
work toward earli launch assum approv
expand ali footprint beyond us
advanc like acceler
report cash cash equival ep loss per share
revenu
recap biolog stumbl ice recoveri ahead
bottom line remain outperform view consumables-heavi portfolio
remain differenti contribut above-industri growth margin life scienc
tool coverag univers came street expect deliv organ
growth vs cn expect driver miss biolog drug qc product
line ice mauric protein platform divis experienc increas competit
segment beckman coulter appear reduc price also
experienc tougher comp rest end-market segment remain solid growth china
deliv strong high-singl digit europ growth academ pt
move
biolog stumbl ice expect recoveri ahead
acd remain under-penetr still expect growth near medium term
degre separ diagnost usual good spot
revenu ep exclud charg amort intang
quarter path near-term debt relief pt
pro-forma ebitda leverag
bottom line maintain mp rate ebitda increas pt
beat path near-term default relief propos debt
exchang volum declin less bad fear beat consensu swb expens improv
make progress cost reduct effort announc tender exchang
note reliev near-term matur default risk expens increas interest
ebitda guidanc midpoint mm vs consensu mm reiter maintain
ebitda mm ebitda mm
revenu ebitda ep beat driven swb improv
volum beat consensu less bad fear
price solid due higher acuiti line trend report op
make progress cost reduct effort
ebitda guidanc midpoint mm reiter vs consensu mm exhibit
debt exchang provid path near-term matur relief
close hospit divestitur expect complet anoth round divestitur
revenu
revenu million bad debt expens ep present ex one-tim item
recap new ceo lend expertis late-stag development/program
track
outperform market cap price price target methodolog dcf
bottom line today achn releas financi result alongsid news major restructur
compani result reduct headcount step former
ceo milind deshpand replac compani exist joseph truitt
convers management describ promot mr truitt reflect compani
late-stage/pre-commerci also mr truitt skill set resid move
repres second c-suit adjust past five month see catalyst
achn load second half year focu remain program involv lead
complement factor inhibitor asset glomerular nephropathi rare kidney
life threaten diseas paroxysm nocturn hemoglobinuria pnh orphan diseas
manifest excess intra-/extravascular lyse red blood cell hemolysi investor anticip
two trial readout program posit could favor posit
achn road becom first-to-market indic addit
wit data report two studi involv pnh market current
domin alexion op soliri taken togeth second half shape
pivot time compani clinic pipelin could swing stock either direct
updat model reflect financi reiter op pt
revenu mm ep
 methodolog ev/ebitda ebitda
bottom line reiter contrarian view strong structur buy hold hospit
name higher pt see weak solid print buy opportun
maintain ebitda see upsid estim believ consensu conserv
better expect ss revenu hospit price growth potenti ebitda margin
expans remaind acquir asset integr core busi
store ss adj admiss growth ex uk low end guidanc even
season weaker quarter expect continu strength even difficult comp time
even see potenti normal growth guidanc exceed current rang
potenti hospit price growth remain structur elev level acuiti servic
line improv impress capac util ambulatori asset base network
access point grow meaning under-valued estim sotp
valuat rang cf gener remain solid capit deploy
capital-expenditure benefit increment mm tax reform tailwind drive ambulatori
expans inpati bed add
revenu million bad debt ep present ex one-tim item
tax rais focu conviva fl medicaid
bottom line beat ep estim tax rate slightli consensu
revenu rais ep guidanc new rang retail
miss quarter flu lower prior period develop benefit enhanc
full year retail guidanc improv bp signal miss
concern group employ specialti beat rate notic offer exclud
estim risk code line yoy increas compar cite
given geographi also offer flexibl supplement benefit upcom sell
season also strong winner fl medicaid contract commenc give
opportun take advantag higher premium fulli integr dual fid recent
legisl bipartisan spend bill membership move increment away risk
capit physician value-bas relationship enhanc perform profit manag
host call edt expect call focu driver perform especi retail
quarter full year guidanc product design strategi fl medicaid contract win
physician network ownership strategi includ conviva speculated-upon deal
part relationship potenti upsel retail distribut conviva recent
anoth setback ido outperform ideal combo still unclear
luspatercept phase iii ev impli upsid celg
stannsoporfin brief document give caus caution head
use discount rate termin growth rate
ep in-lin revenu allow continu
modest miss adj ebitda adj ep in-lin ebitda guidanc
cheap enough yet fall short pipelin depend crowd ra
 methodolog averag price-to-earnings large-cap revenu multipl slower-growth
medic co sum part exist franchis dcf
 methodolog normal ep
recap attr ind preclin work indic continu
 methodolog ev/sal multipl appli sale
 methodolog ev/ebitda analysi sotp estim rang
recap solid quarter execut start drive test volum
 rais pois year rais ep pt
sotp impli ev/sal
hcit distribut transit analyt value-bas continu
healthcar distribut volum price look suppli chain preview
healthcar facil in-line posit catalyst would
also posit
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
may genesight data present pharmacogenom test
believ data present american psychiatr associ confer
provid insight secondari genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project pku
june american societi clinic oncolog
year meet updat patient treat combin
lead candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
view agent novel chemic structur avoid format presum toxic
metabolit good reason atogep could avoid liver toxic seen
telcagep follow-on compound
support view gen molecul calcitonin gene-rel peptid cgrp
may avoid liver safeti risk management report un-blind look liver enzym
elev agn on-going atogep studi line placebo event rate
clinic studi
atogep deliv efficaci profil within strike distanc inject
good safeti toler work suggest sizabl market opportun base
inject categori oral late entrant xeljanz rheumatoid arthriti otezla
psoriasi
believ program good chanc success view success
atogep migrain prevent would offer signific valid agn open-sci
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
scph lead asset furoscix at-hom diuresi anticip pdufa action date
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
sourc leerink research compani inform factset price prior day
fda adcom gastrointestin drug pediatr stannsoporfin infect
link note
fda adcom endocrinolog metabol drug
fda jtn adcom pediatr endocrinolog metabol drug
fda adcom vaccin relat biolog product
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda adcom anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
associ research vision ophthalmolog nite
american societi pediatr hematology/oncolog
intern societi cellular therapi
american societi breast surgeon
american associ immunologist
american associ orthodontist
pan american societi clinic virolog
european societi pediatr gastroenterolog hepatolog nutrit
societi biolog psychiatri
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi
american associ clinic endocrinologist updat afirma
societi neurolog surgeon
world feder hemophilia link
european academi allergi clinic immunolog
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
uk take-over code may make decis respect
potenti bid shire
hcit distribut transit analyt value-bas continu
healthcar distribut volum price look suppli chain preview
healthcar facil in-line posit catalyst would
also posit
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo rewind
biopharma -- flash highlight invokana fda warn puls call modest impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco -- flash inclisiran lesson fourier/odyssey may better
mdco anoth step forward cubist vabomer approv pt outperform
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma name shame california latest strategi rein drug price
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
 elast demand consist reduc price drive volum growth
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
